Answers are grounded in this paper and cite their sources.
Importance Postoperative recurrence remains a major challenge after primary pterygium surgery, and whether grafting approaches are more effective than intraoperative mitomycin C (MMC) in reducing recurrence remains uncertain. Objective To determine whether grafting with conjunctival autograft (CAG) or amniotic membrane transplant (AMT) is superior to MMC in preventing 1-year recurrence after primary pterygium excision. Design, Setting, and Participants This multicenter, open-label randomized clinical trial with masked outcome assessment with 12-month follow-up was conducted at 5 tertiary hospitals in China. Enrollment and follow-up occurred between January 2016 and December 2020, and data were analyzed from September 2025 through January 2026. Patients aged 18 to 80 years with primary pterygium were enrolled and randomly assigned 1:1:1 to AMT (n = 249), MMC (n = 248), or CAG (n = 253). Interventions Standardized pterygium excision with conjunctival excision extending radially 4 mm from the limbus, combined with AMT, MMC, or CAG. Main Outcomes and Measures The primary outcome was 12-month postoperative recurrence. Secondary outcomes included best-corrected visual acuity, epithelial healing time, and conjunctival congestion scores. Results Of 750 randomized participants (mean [SD] age, 57.2 [10.5] years; 487 women [64.9%]), 681 (90.8%) completed follow-up. Recurrence in the intention-to-treat analysis was 57 participants of 249 with AMT (22.9%), 34 of 248 with MMC (13.7%), and 13 of 253 with CAG (5.0%). Risk differences were 9.2 percentage points for AMT vs MMC (98.33% CI, 0.6-17.9; P = .01), 17.9 for AMT vs CAG (98.33% CI, 10.5-25.4; P < .001), and 8.7 for MMC vs CAG (98.33% CI, 2.2-15.2; P = .001). Risk ratios were 1.69 (98.33% CI, 0.99-2.91; P = .02), 4.62 (98.33% CI, 2.14-9.97; P < .001), and 2.73 (98.33% CI, 1.20-6.20; P = .004), respectively. Complete-case analyses yielded similar results. Adverse events occurred in 18 of 249 AMT participants (7.2%), 28 of 248 MMC participants (11.3%), and 16 of 253 CAG participants (6.3%), with no intervention-related serious adverse events. Conclusions and Relevance In this randomized clinical trial, among patients undergoing primary pterygium excision, recurrence was lowest with CAG, intermediate with MMC, and highest with AMT. The moderate magnitude of the between-procedure differences makes recurrence prevention an important—but not exclusive—determinant of surgical choice and may inform individualized surgical management. Trial Registration ClinicalTrials.gov Identifier: NCT02102776
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: